AvantGen

Adagene has created a platform composed of unique, multi-purpose, antibody technologies and a growing pipeline of leading assets with novel MOAs. Empowered by precision engineering, Adagene identifies and selects antibody candidates that are most likely to achieve the desired biological effects. Our core technology is built upon our fundamental understanding of the role that protein folding and the motion of molecules play in giving rise to dynamic conformational diversity, where an amino acid sequence can adopt multiple structures and functions.

With our innovative technologies and team of experts, we are supporting the scientific community to Achieve their goals, Advance their knowledge about protein interactions and make new Discoveries.We ought to be the best Y2H based and nanobody partner to make breaktroughs possible. Working with Hybrigenics staff is more like having a collaborator than a service provider…staff is very knowledgeable and highly responsive..their expertise and novel methodology gives high hit.. They undertook our project as a research collaboration with a goal to deliver us reliable/high quality data. Staff were in constant communication and consultation with us the entire way, and ultimately provided a set of novel high-confidence MYC interactors that we still work on to this day. Working with Hybrigenics staff is more like having a collaborator than a service provider…staff is very knowledgeable and highly responsive..their expertise and novel methodology gives high hit reliability.

We are an extension of your lab and are part of your team working together towards a common goal. Custom projects managed from antigen design through production, purification and characterization. Combining our deep knowledge base with years of hands-on experience, we can deliver what you need, when you need it and on budget. GMAb provides excellent services related to monoclonal antibody technology, including the development of novel antibodies, immunoassay design and methods for antibody characterization.

GigaGen’s novel technology platforms uniquely capture and recreate complete immune repertoires as functional antibody libraries. GigaGen’s lead oncology asset, GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo through a unique mechanism of action. GigaGen is leveraging its proprietary technology platforms for the continued discovery of novel recombinant polyclonal drugs and monoclonal antibodies to treat life-threatening diseases. GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal Antibodies. GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development. GigaGen Licenses ProteoNic’s 2G UNic Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates. Biocentury: GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute. GigaGen’s platform technologies significantly increase the productivity and speed of target and drug discovery, quickly filling a growing pipeline of transformative antibody drugs.

We provide high-end antibody discovery workflows four times faster than conventional state-of-the-art processes. We are very convinced of the quality of their work and the reliability and passion to solve any custom-related issues. We offer the customized generation and production of mouse, camelid, and human antibodies for various in vitro and in vivo applications. Founded in 2014 as an university spin-off located at the Potsdam Science Park the company is embedded in a vibrant scientific environment. To increase the efficacy of this process we developed a hyper-immunization protocol based on viral carrier proteins. In combination with selma as selection tool we provide a high end solution for the discovery of antibody producing hybridoma cells four times faster than with conventional methods. This is a very interesting feature for in vitro diagnostic applications. Creating innovative antibodies with new/era/mabs was a snap.

We are world leaders in antibody development services specializing in the discovery, engineering and supply of pre-clinical biologics to clinical Cell Line Development. Established in 2001, Fusion Antibodies is a Collaborative Research Organisation (CRO) with its headquarters in Northern Ireland. Fusion offers flexibility and agility while delivering clinical candidates focusing on developability, manufacturability and function. We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. We offer a complete end-to-end service from antigen design to cell line development. We work in partnership as an extension of your team to deliver the project requirements while also considering long term goals of manufacturability and commercialization. According to this CMO, the antibody is the poster child for the best producing and most well-behaved antibody they have seen to date, and it will serve as the benchmark to match or exceed for their future projects.